益方生物2024年亏损收窄至2.4亿元

财中社2025-04-27

4月25日，益方生物(688382)公布2024年年报，公司营业收入为1.69亿元，同比下降9.0%；归母净利润自去年同期亏损2.84亿元变为亏损2.4亿元，亏损额有所减少；扣非归母净利润自去年同期亏损2.94亿元变为亏损2.5亿元，亏损额有所减少；经营现金流净额为-2.42亿元，同比增长21.4%；EPS(全面摊薄)为-0.4165元。其中第四季度，公司营业收入为1.5亿元，同比上升156.4%...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2530109738?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-27 09:27","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2530109738","market":"sh","top_or_hot":-1,"title":"益方生物2024年亏损收窄至2.4亿元","media":"财中社","content":"<div>\n<p>4月25日，益方生物(688382)公布2024年年报，公司营业收入为1.69亿元，同比下降9.0%；归母净利润自去年同期亏损2.84亿元变为亏损2.4亿元，亏损额有所减少；扣非归母净利润自去年同期亏损2.94亿元变为亏损2.5亿元，亏损额有所减少；经营现金流净额为-2.42亿元，同比增长21.4%；EPS(全面摊薄)为-0.4165元。其中第四季度，公司营业收入为1.5亿元，同比上升156.4%...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042709281694e43e68&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>益方生物2024年亏损收窄至2.4亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n益方生物2024年亏损收窄至2.4亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-27 09:27 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042709281694e43e68&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月25日，益方生物(688382)公布2024年年报，公司营业收入为1.69亿元，同比下降9.0%；归母净利润自去年同期亏损2.84亿元变为亏损2.4亿元，亏损额有所减少；扣非归母净利润自去年同期亏损2.94亿元变为亏损2.5亿元，亏损额有所减少；经营现金流净额为-2.42亿元，同比增长21.4%；EPS(全面摊薄)为-0.4165元。其中第四季度，公司营业收入为1.5亿元，同比上升156.4%...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042709281694e43e68&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042709281694e43e68&s=b","article_id":"2530109738","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042709281694e43e68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2530109738","pubTimestamp":1745717270,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"4月25日，益方生物公布2024年年报，公司营业收入为1.69亿元，同比下降9.0%；归母净利润自去年同期亏损2.84亿元变为亏损2.4亿元，亏损额有所减少；扣非归母净利润自去年同期亏损2.94亿元变为亏损2.5亿元，亏损额有所减少；经营现金流净额为-2.42亿元，同比增长21.4%；EPS为-0.4165元。截至四季度末，公司总资产19.21亿元，较上年度末下降11.2%；归母净资产为18.11亿元，较上年度末下降9.4%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688382":"益方生物-U","BK0239":"医药制造"},"translate_title":"Yifang Biotech's loss will narrow to 240 million yuan in 2024","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688382":1},"content_text":"4月25日，益方生物(688382)公布2024年年报，公司营业收入为1.69亿元，同比下降9.0%；归母净利润自去年同期亏损2.84亿元变为亏损2.4亿元，亏损额有所减少；扣非归母净利润自去年同期亏损2.94亿元变为亏损2.5亿元，亏损额有所减少；经营现金流净额为-2.42亿元，同比增长21.4%；EPS(全面摊薄)为-0.4165元。其中第四季度，公司营业收入为1.5亿元，同比上升156.4%；归母净利润自去年同期亏损4271万元成功扭亏，实现归母净利润6510万元；扣非归母净利润自去年同期亏损4571万元成功扭亏，实现扣非归母净利润6307万元；EPS为0.1129元。截至四季度末，公司总资产19.21亿元，较上年度末下降11.2%；归母净资产为18.11亿元，较上年度末下降9.4%。公司在2024年年度报告中提到，临床管线持续推进，整体研发投入保持在较高水平。报告期内，主要产品的临床研究取得重要进展，特别是KRASG12C抑制剂格索雷塞在2024年11月获得批准上市。此外，口服选择性雌激素受体降解剂D-0502正在进行关键注册Ⅲ期临床试验，TYK2抑制剂D-2570的银屑病II期临床试验也顺利完成。公司在技术授权和合作方面实现了一定的收入，尤其是对外授权的两款产品贝福替尼和格索雷塞的上市销售为公司带来了销售提成收益。整体来看，公司在产品研发和临床进展上表现积极，继续聚焦于肿瘤、代谢及自身免疫性疾病领域的创新药物开发。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2530109738","isCrawlerRequest":true}